01 February 2023 : Database Analysis
Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
Marcin Warpechowski1CD, Jędrzej Warpechowski2AEF*, Anita Pieńkowska3BEF, Szymon Sagała2BEF, Robert Milewski
4CDE
DOI: 10.12659/MSM.938827
Med Sci Monit 2023; 29:e938827
Figure 1 Box-plot comparison between average value of neutrophil-to-platelet ratio during the induction phase between patients with sustained response and loss of response to infliximab or vedolizumab. Small squares represent the median value. The figure was created using Statistica version 13 (TIBCO Software, Inc.).